Phase 3CompletedAge-related condition

Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder

Comparison of the Efficacy and Tolerability of DITROPAN XL and DETROL LA in the Treatment of Overactive Bladder

Sponsor
Alza Corporation, DE, USA (Industry)
Enrollment
790 enrolled
Conditions
Urinary Incontinence
Interventions
oxybutynin chloride
Ages
adults, older adults
Registry
NCT00293839

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.

Primary outcomes

  • The number of weekly urge urinary incontinence (Urge-UI) episodes at week 12, adjusted for the baseline value

History

  1. Last registry update

  2. Registered

  3. Study completion